Article Sidebar

pdf
Date Published: 24/11/2023
Abstract Views: 82
Views pdf: 65
DOI: https://doi.org/10.51298/vmj.v532i1.7294
Issue
Vol. 532 No. 1 (2023)
Section
Các bài báo
How to Cite
Hoàng, Đình Âu, & Trương, T. T. (2023). THE ROLE OF ZONE VOLUME-ADJUSTED DENSITY PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS OF TRANSITIONAL ZONE PROSTATE CANCER. Vietnam Medical Journal, 532(1). https://doi.org/10.51298/vmj.v532i1.7294

THE ROLE OF ZONE VOLUME-ADJUSTED DENSITY PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS OF TRANSITIONAL ZONE PROSTATE CANCER

Đình Âu Hoàng1,, Thị Thanh Trương1
1 Hanoi Medical University Hospital

Main Article Content

Abstract

Purpose: To evaluate the role of zone volume-adjusted transitional zone (VTZ) of prostate-specific antigen density (PSAd) in the diagnosis of transitional zone cancer. Material and methods: Descriptive study on 60 patients with suspected prostate cancer, PSA test, transition zone lesion nodules on MRI, who had prostate biopsy under transrectal ultrasound guided at Hanoi Medical University Hospital from February 2019 to May 2022. Total prostate volume (Vt) and transition zone volume (VTZ) were measured on MRI. Compare the values of total PSA (PSAt), density PSA (PSAd) and transitional density PSA (PSAdTZ) between cancer of TZ and non-cancer groups, established ROC curve and compare diagnostic value of these parameters. Results: The mean age of the patients was 65.8±8. The mean total volume of prostate (Vt) was 57.9±42.1 cm3. The mean volume of the prostate transition zone (VTZ) was 38.1±34.6 cm3. The mean value of PSAt was 29.8±25.8 ng/ml, that of PSAd was 0.68±0.61 ng/ml2, of PSAdTZ was 1.4±1.5 ng/ml2. There were 27 cancerous and 33 non-cancerous patients. There was a statistically significant difference between the cancer group and the non-cancer groups in terms of Vt (p=0.01), VTZ (p=0.001), PSAt (p=0.04), PSAd (p=0.005) and PSAdTZ (p=0.003). The diagnostic value for transition zone cancer of Vt, VTZ, PSAt, PSAd and PSAdTZ was 0.71; 0.77; 0.67; 0.74 and 0.77, respectively. With a cut-off value of PSAdTZ of 0.74 ng/ml2, the sensitivity and specificity for diagnosing of TZ cancer were 74% and 70%, respectively. Conclusion: PSAdTZ was more valuable than PSAt as well as PSAd in the diagnosis of prostate transition zone cancer. It was necessary to use PSAdTZ instead of PSAt or PSAd to screen for transition zone prostate cancer in order to reduce false-positive cases.

Article Details

Keywords

: Total PSA, density PSA, prostate transition zone cancer

References

1. Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175–181.
2. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2 Pt 1):407–413.
3. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147(3 Pt 2):815–816.
4. Rosenkrantz AB, Kim S, Campbell N, Gaing B, Deng F-M, Taneja SS. Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. American Journal of Roentgenology. 2015;204(3):W266-W272.
5. Kalish J, Cooner WH, Graham SD., Jr Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994;43:601–606.
6. Kang SH, Bae JH, Park HS, Yoon DK, Moon DG, Kim JJ, et al. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases. Int J Urol. 2006;13:910–914.
7. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56:255–260.
8. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214–1220.
9. Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol. 1997;158:2162–2167.
10. Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol. 1993;150(2 Pt 1):369–373.